MLN8237: Phase II data

An ongoing, open-label, U.S. Phase II trial in 41 evaluable patients with relapsed or refractory aggressive B cell or T cell NHL showed that twice-daily 50 mg oral MLN8237 given on days 1-7 of a 21-da...